Finerenone + SGLT2 inhibitors + GLP-1 receptor agonists

1. Finerenone + SGLT2 inhibitors + GLP-1 receptor agonists have no effect on urinary albumin-to-creatinine ratio in humans (-0.323 (95% CI: -0.912 to +0.266)).

   Humansadjusted between-group difference in T2DM-related CKD6 months

   Finerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort Study

   Clinical therapeutics·8 Sep 2026

2. Finerenone + SGLT2 inhibitors + GLP-1 receptor agonists decrease urinary albumin-to-creatinine ratio in humans (-46.9% (95% CI 27.0-61.3%)).

   Humansin adults with T2DM-related CKD6 months

   Finerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort Study

   Clinical therapeutics·8 Sep 2026

More on Urinary albumin-to-creatinine ratio

1. Finerenone + SGLT2 inhibitors + GLP-1 receptor agonists are associated with estimated glomerular filtration rate in humans (+6.407 mL/min/1.73 m2 (95% CI: +0.297 to +12.52)).

   Humanscompared with dual therapy in T2DM-related CKD6 months

   Finerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort Study

   Clinical therapeutics·8 Sep 2026

More on Estimated glomerular filtration rate